Sign Up Today and Learn More About Civatech Oncology Stock
Invest in or calculate the value of your shares in Civatech Oncology or other pre-IPO companies through EquityZen's platform.
Civatech Oncology Stock (CION)
Civatech Oncology is a medical device company that develops polymer-based devices to treat cancer using localized low-dose-rate radiation.
About Civatech Oncology Stock
Founded
2006
Headquarters
Durham, NC, US
Industries
Science and Engineering, Health Care, Biotechnology
Civatech Oncology is a medical device company that develops polymer-based devices to treat cancer using localized low-dose-rate radiation. Because polymers are easy to manufacture in different shapes and formats, CivaTech's patented and patent-pending technology enables devices that can be designed and fabricated for specific tumor types. Its first product, the CivaString, has been granted FDA 510k clearance to treat any solid tumor. The company was founded in 2006 and is based in Durham, North Carolina, United States.
Civatech Oncology Press Mentions
Stay in the know about the latest news on Civatech Oncology
CivaTech Oncology selected to present at BIO International Conference
biospace • Jun 29, 2022
Morrisville’s CivaTech Oncology raises more than $7.9M and could raise more
wraltechwire • Nov 23, 2021
CivaDerm™ - CivaTech Oncology’s New Skin Cancer Therapy Product Receives FDA Clearance
businesswire • Oct 01, 2019
NC Biotech Center-backed companies raise $11M to close 2016
wraltechwire • Jan 22, 2017
Civatech Oncology Management
Leadership team at Civatech Oncology
Co-Founder & Executive Chairman
Suzanne Troxler Babcock
Attorney-in-fact
Merrill M. Mason
Join now and verify your accreditation status to gain access to:
- Civatech Oncology current valuation
- Civatech Oncology stock price
- Available deals in Civatech Oncology and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Civatech Oncology Stock
How to invest in Civatech Oncology stock?
Accredited investors can buy pre-IPO stock in companies like Civatech Oncology through EquityZen funds. These investments are made available by existing Civatech Oncology shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Civatech Oncology stock?
Shareholders can sell their Civatech Oncology stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
